Meglitinides Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Meglitinide Market is segmented by geography. The report offers the value (in USD million) and volume (in units million) for the above segments.

Meglitinides Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Meglitinide Market Size

Meglitinide Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 4.45 Billion
Market Size (2030) USD 4.96 Billion
CAGR (2025 - 2030) 2.21 %
Fastest Growing Market Middle East and Africa
Largest Market Asia-Pacific

Major Players

Meglitinide Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Meglitinide Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Meglitinide Market Analysis

The Meglitinide Market size is estimated at USD 4.45 billion in 2025, and is expected to reach USD 4.96 billion by 2030, at a CAGR of 2.21% during the forecast period (2025-2030).

During the COVID-19 pandemic people with diabetes were more likely to have serious complications from COVID-19. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. Thus, the COVID-19 outbreak increased the meglitinide market's growth globally.

Meglitinides are a class of non-sulfonylurea insulin secretagogues characterized by very rapid onset and shorter duration of action. They stimulate first-phase insulin release in a glucose-sensitive manner, reducing the risk of hypoglycemic events. People with type 2 diabetes have chronically high blood sugar levels and meglitinides make the body free up more insulin.

The World Health Assembly agreed on a Resolution on strengthening the prevention and control of diabetes in may 2021 which recommends action in areas including increasing access to medicines and health products for the treatment of diabetes. According to International Diabetes Federation (IDF), the adult diabetes population in 2021 is approximately 537 million, and this number is going to increase by 643 million in 2030. The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure worldwide are indications of the increasing usage of anti-diabetic drugs. Technological advancements and innovations have increased over the period leading to several modifications either in the drugs or the formulations being developed.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Meglitinide Industry Overview

The meglitinide market is fragmented, with manufacturers like Novo Nordisk, Glenmark, and Novartis etc. having a global market presence and the market is highly competitive due to generic drugs manufacturers' presence.

Meglitinide Market Leaders

  1. Glenmark Pharmaceuticals

  2. Novartis

  3. Kissei Pharmaceuticals

  4. Biocon

  5. Novo Nordisk A/S

  6. *Disclaimer: Major Players sorted in no particular order
Meglitinide Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Meglitinide Market News

  • March 2023: A Randomized, Open-Label, Controlled, Parallel-group, Multicenter Trial was conducted to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type-2 diabetes not adequately controlled with oral antidiabetic drugs compared to insulin Glargine QD for 26+26 weeks.
  • January 2023: OXJournal reviewed the effects of meglitinides as a class of oral medications for treating type 2 diabetes, especially in young adults.

Meglitinide Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Geography
    • 5.1.1 North America
    • 5.1.1.1 United States
    • 5.1.1.2 Canada
    • 5.1.1.3 Rest of North America
    • 5.1.1.4
    • 5.1.2 Europe
    • 5.1.2.1 Germany
    • 5.1.2.2 Spain
    • 5.1.2.3 Italy
    • 5.1.2.4 France
    • 5.1.2.5 United Kingdom
    • 5.1.2.6 Russia
    • 5.1.2.7 Rest of Europe
    • 5.1.3 Asia-Pacific
    • 5.1.3.1 Japan
    • 5.1.3.2 China
    • 5.1.3.3 Australia
    • 5.1.3.4 India
    • 5.1.3.5 South Korea
    • 5.1.3.6 Malaysia
    • 5.1.3.7 Indonesia
    • 5.1.3.8 Thailand
    • 5.1.3.9 Vietnam
    • 5.1.3.10 Philippines
    • 5.1.3.11 Rest of Asia-Pacific
    • 5.1.4 Latin America
    • 5.1.4.1 Brazil
    • 5.1.4.2 Mexico
    • 5.1.4.3 Rest of Latin America
    • 5.1.5 Middle East and Africa
    • 5.1.5.1 South Africa
    • 5.1.5.2 Saudi Arabia
    • 5.1.5.3 Oman
    • 5.1.5.4 Egypt
    • 5.1.5.5 Iran
    • 5.1.5.6 Rest of Middle East and Africa

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Biocon
    • 7.1.2 Boehringer Ingelheim
    • 7.1.3 Bristol Myers Squibb
    • 7.1.4 Glenmark
    • 7.1.5 Kissei Pharmaceuticals
    • 7.1.6 Mylan
    • 7.1.7 Novartis
    • 7.1.8 Novo Nordisk
    • 7.1.9 Pfizer
    • 7.1.10 Teva Pharmaceuticals
  • *List Not Exhaustive
  • 7.2 MARKET SHARE ANALYSIS
    • 7.2.1 Boehringer Ingelheim
    • 7.2.2 Novartis
    • 7.2.3 Novo Nordisk
    • 7.2.4 Other Market Share Analyses

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*The report covers a segment-wise breakdown (Value and Volume) for all the countries covered under Table of Contents **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Meglitinide Industry Segmentation

Meglitinides, or glinides, are a class of drugs used to treat type-2 diabetes. Meglitinides work by stimulating the pancreas to release insulin in response to a meal. The meglitinide market is segmented by geography (United States, Canada, and the rest of North America). The report offers the value (in USD) and volume (in units) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.

Geography North America United States
Canada
Rest of North America
Europe Germany
Spain
Italy
France
United Kingdom
Russia
Rest of Europe
Asia-Pacific Japan
China
Australia
India
South Korea
Malaysia
Indonesia
Thailand
Vietnam
Philippines
Rest of Asia-Pacific
Latin America Brazil
Mexico
Rest of Latin America
Middle East and Africa South Africa
Saudi Arabia
Oman
Egypt
Iran
Rest of Middle East and Africa
Need A Different Region or Segment?
Customize Now

Meglitinide Market Research FAQs

How big is the Meglitinide Market?

The Meglitinide Market size is expected to reach USD 4.45 billion in 2025 and grow at a CAGR of 2.21% to reach USD 4.96 billion by 2030.

What is the current Meglitinide Market size?

In 2025, the Meglitinide Market size is expected to reach USD 4.45 billion.

Who are the key players in Meglitinide Market?

Glenmark Pharmaceuticals, Novartis, Kissei Pharmaceuticals, Biocon and Novo Nordisk A/S are the major companies operating in the Meglitinide Market.

Which is the fastest growing region in Meglitinide Market?

Middle East and Africa is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Meglitinide Market?

In 2025, the Asia-Pacific accounts for the largest market share in Meglitinide Market.

What years does this Meglitinide Market cover, and what was the market size in 2024?

In 2024, the Meglitinide Market size was estimated at USD 4.35 billion. The report covers the Meglitinide Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Meglitinide Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Meglitinides Industry Report

Statistics for the 2025 Meglitinide market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Meglitinide analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.